Are you over 18 and want to see adult content?
More Annotations
A complete backup of qualityservicemanual.com
Are you over 18 and want to see adult content?
A complete backup of sheddoorsnmore.com
Are you over 18 and want to see adult content?
A complete backup of anunsman.tumblr.com
Are you over 18 and want to see adult content?
A complete backup of thelittlereddog.com
Are you over 18 and want to see adult content?
A complete backup of injuryjournal.com
Are you over 18 and want to see adult content?
A complete backup of armacoopcorps.pl
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of www.amateuralbum.net
Are you over 18 and want to see adult content?
A complete backup of www.planetsuzy.org
Are you over 18 and want to see adult content?
A complete backup of www.quartier-rouge.be
Are you over 18 and want to see adult content?
A complete backup of www.overthedesk.com
Are you over 18 and want to see adult content?
A complete backup of www.coedcherry.com
Are you over 18 and want to see adult content?
A complete backup of travestismexico.com
Are you over 18 and want to see adult content?
Text
IDIBELL
Hospital Duran i Reynals 3a planta / Gran Via de l’Hospitalet, 199 08908 Hospitalet de Llobregat IDIBELLTRANSLATE THIS PAGECOL·LABORACONTACTEINTRANETPROVEÏDORSOFERTES DE FEINAACTUALITAT IDIBELL. Societat. Treballem per millorar la salut de les persones. Col·labora. Recerca. Càncer, neurociències, medicina translacional i regenerativa. Àrees de recerca. Innovació. Del laboratori alTHE INSTITUTE
The Bellvitge Biomedical Research Institute (IDIBELL) is a research center in biomedicine promoted by the Bellvitge University Hospital and l’Viladecans Hospital, both from the Catalan Health Institute, the Catalan Institute of Oncology, University of Barcelona and L’Hospitalet de Llobregat city council.In 2017, the Center for Regenerative Medicine of Barcelona (CMR), now part of IDIBELL RESEARCHERS IDENTIFY THREE CLINICAL PROFILES OF A study published in The Lancet Infectious Diseases, in which Bellvitge University Hospital (HUB) and the Bellvitge Biomedical Research Institute (IDIBELL) have participated, has identified three phenotypes (clinical profiles or forms of patient presentation) of COVID-19, each with a RECERCA – IDIBELLTRANSLATE THIS PAGE L'Institut de Recerca Biomèdica de Bellvitge (IDIBELL) és un centre de recerca orientat vers la millora dels problemes de salut de les persones.Per aconseguir-ho és necessari dur a terme recerca bàsica i clínica d’alt nivell. L’IDIBELL té investigadors propis i integra la recerca que es duu a terme a l’Hospital Universitari de Bellvitge, l’Hospital de Viladecans (ambdós de lOFERTES DE FEINA
Sobre la política de l'IDIBELL de contractació oberta, transparent i basada en el mèrit. L'IDIBELL ha actualitzat l'estratègia de recursos humans i els seus procediments de contractació d'investigadors, suport científic i personal de suport a la gestió per assegurar la selecció dels candidats més idonis mitjançant una contractació oberta, transparent i basada en el mèrit (OTM-R).ARETE.IDIBELL.CAT
2019 Bellvitge Biomedical Research Institute. All rights reserved.X
PHARMACOVIGILANCE TECHNICIAN FOR CLINICAL RESEARCH UNIT IN IDIBELL is looking for Pharmacovigilance Technician (FV) for Clinical Research Unit in Clinical Trials (UICEC IDIBELL) Our institute. IDIBELL is a research center that integrates the biomedical research of the Bellvitge University Hospital (HUB), the Catalan Institute of Oncology (ICO), and the University of Barcelona in the Bellvitge Campus (UB), and the Viladecans Hospital (HV). GABRIEL CAPELLÁ, DIRECTOR OF IDIBELL The Board of Bellvitge Biomedical Research Institute (IDIBELL), in its meeting of December 29 th, has approved the appointment of. Dr. Gabriel Capellá as director of IDIBELL. This decision puts an end to the selection process started last July, when Dr. Jaume Reventós became coordinator of strategy and institutional relations of the General Directorate for Research and Innovation in Health. IDIBELL - INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGETRANSLATE THISPAGE
Encara no heu confirmat l'asistencia al curs de programacio en R programat pel dia 29-30 de juny i 6-7 de juliol, la data limit per fer la confirmaci� es el dia 09/06/2017IDIBELL
Hospital Duran i Reynals 3a planta / Gran Via de l’Hospitalet, 199 08908 Hospitalet de Llobregat IDIBELLTRANSLATE THIS PAGECOL·LABORACONTACTEINTRANETPROVEÏDORSOFERTES DE FEINAACTUALITAT IDIBELL. Societat. Treballem per millorar la salut de les persones. Col·labora. Recerca. Càncer, neurociències, medicina translacional i regenerativa. Àrees de recerca. Innovació. Del laboratori alTHE INSTITUTE
The Bellvitge Biomedical Research Institute (IDIBELL) is a research center in biomedicine promoted by the Bellvitge University Hospital and l’Viladecans Hospital, both from the Catalan Health Institute, the Catalan Institute of Oncology, University of Barcelona and L’Hospitalet de Llobregat city council.In 2017, the Center for Regenerative Medicine of Barcelona (CMR), now part of IDIBELL RESEARCHERS IDENTIFY THREE CLINICAL PROFILES OF A study published in The Lancet Infectious Diseases, in which Bellvitge University Hospital (HUB) and the Bellvitge Biomedical Research Institute (IDIBELL) have participated, has identified three phenotypes (clinical profiles or forms of patient presentation) of COVID-19, each with a RECERCA – IDIBELLTRANSLATE THIS PAGE L'Institut de Recerca Biomèdica de Bellvitge (IDIBELL) és un centre de recerca orientat vers la millora dels problemes de salut de les persones.Per aconseguir-ho és necessari dur a terme recerca bàsica i clínica d’alt nivell. L’IDIBELL té investigadors propis i integra la recerca que es duu a terme a l’Hospital Universitari de Bellvitge, l’Hospital de Viladecans (ambdós de lOFERTES DE FEINA
Sobre la política de l'IDIBELL de contractació oberta, transparent i basada en el mèrit. L'IDIBELL ha actualitzat l'estratègia de recursos humans i els seus procediments de contractació d'investigadors, suport científic i personal de suport a la gestió per assegurar la selecció dels candidats més idonis mitjançant una contractació oberta, transparent i basada en el mèrit (OTM-R).ARETE.IDIBELL.CAT
2019 Bellvitge Biomedical Research Institute. All rights reserved.X
PHARMACOVIGILANCE TECHNICIAN FOR CLINICAL RESEARCH UNIT IN IDIBELL is looking for Pharmacovigilance Technician (FV) for Clinical Research Unit in Clinical Trials (UICEC IDIBELL) Our institute. IDIBELL is a research center that integrates the biomedical research of the Bellvitge University Hospital (HUB), the Catalan Institute of Oncology (ICO), and the University of Barcelona in the Bellvitge Campus (UB), and the Viladecans Hospital (HV). GABRIEL CAPELLÁ, DIRECTOR OF IDIBELL The Board of Bellvitge Biomedical Research Institute (IDIBELL), in its meeting of December 29 th, has approved the appointment of. Dr. Gabriel Capellá as director of IDIBELL. This decision puts an end to the selection process started last July, when Dr. Jaume Reventós became coordinator of strategy and institutional relations of the General Directorate for Research and Innovation in Health. IDIBELL - INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGETRANSLATE THISPAGE
Encara no heu confirmat l'asistencia al curs de programacio en R programat pel dia 29-30 de juny i 6-7 de juliol, la data limit per fer la confirmaci� es el dia 09/06/2017THE INSTITUTE
The Bellvitge Biomedical Research Institute (IDIBELL) is a research center in biomedicine promoted by the Bellvitge University Hospital and l’Viladecans Hospital, both from the Catalan Health Institute, the Catalan Institute of Oncology, University of Barcelona and L’Hospitalet de Llobregat city council.In 2017, the Center for Regenerative Medicine of Barcelona (CMR), now part ofSCIENTIFIC CULTURE
Scientific Culture and Innovation Unit (UCC+i) IDIBELL follows the model on responsible research and innovation (RRI) that the European Union proposes and is developing. Proof of this was the creation, at the end of 2017, of the Scientific Culture and Innovation Unit (UCC+i), accredited by the Spanish Foundation for Science andTechnology (FECyT).
SCIENCE AND PERFORMING ARTS AGAINST STEREOTYPES A study by IDIBELL and UB shows that participation in a workshop combining scientific training and theatre performance reduces implicit biases against physical illnesses THE IMPACT OF THE PANDEMIC ON PEOPLE WITH EATING DISORDERS The impact of the pandemic on people with eating disorders and obesity. Dr. Fernando Fernández-Aranda is a principal investigator in the Psychiatry and Mental Health Group at IDIBELL, coordinator of the Eating Disorders Unit at Bellvitge University Hospital, and Head of the CIBER Obesity and Nutrition Group. He is currently theeditor-in-chief
RECERCA – IDIBELLTRANSLATE THIS PAGE L'Institut de Recerca Biomèdica de Bellvitge (IDIBELL) és un centre de recerca orientat vers la millora dels problemes de salut de les persones.Per aconseguir-ho és necessari dur a terme recerca bàsica i clínica d’alt nivell. L’IDIBELL té investigadors propis i integra la recerca que es duu a terme a l’Hospital Universitari de Bellvitge, l’Hospital de Viladecans (ambdós de l OCCUPATIONAL RISK PREVENTION MANAGER IDIBELL is looking for an Occupational Risk Prevention Manager . Our institute. IDIBELL is a research center that integrates the biomedical research of the Bellvitge University Hospital (HUB), the Catalan Institute of Oncology (ICO), and the University of Barcelona in the Bellvitge Campus (UB), and the Viladecans Hospital (HV). CLINICAL RESEARCH ASSOCIATE FOR THE CLINICAL RESEARCH AND IDIBELL is looking for Clinical Research Associate (CRA) for the Clinical Research and Clinical Trials Unit (UICEC IDIBELL) Our institute. IDIBELL is a research center that integrates the biomedical research of the Bellvitge University Hospital (HUB), the Catalan Institute of Oncology (ICO), and the University of Barcelona in the Bellvitge Campus (UB), and the Viladecans Hospital (HV).AMP IDIBELL
AMP I (1st edition) The Bellvitge Biomedical Research Institute (IDIBELL) held yesterday April 16th the first edition of its. Accelerator Meeting Point, a meeting where CataloniaBio -association of biomedicine and health. companies in Catalonia-, Biocat -institution responsible for the promotion of IDIBELL - BELLVITGE BIOMEDICAL RESEARCH INSTITUTE Domain: www.idibell.cat Owner: Fundació Institut d’Investigació Biomèdica de Bellvitge (IDIBELL). Address: Hospital Duran i Reynals, 3rd floor, Gran Via de l’Hospitalet, 199-203, 08908 L’Hospitalet de Llobregat (Barcelona). Telephone: 93 260 74 11. Electronic mail address: idibell@idibell.cat. Registration data: registered in the Register of Foundations under number 459STEM CELL AGING
Somatic stem cells have the ability to regenerate tissues over time. This capacity declines with age, disrupting tissue maintenance. Understanding how stem cells age and identifying intervention strategies to maintain stem cell regenerative capacity will lead to new therapeutic approaches for maintaining our health as we age.IDIBELL
Hospital Duran i Reynals 3a planta / Gran Via de l’Hospitalet, 199 08908 Hospitalet de Llobregat IDIBELLTRANSLATE THIS PAGECOL·LABORACONTACTEINTRANETPROVEÏDORSOFERTES DE FEINAACTUALITAT IDIBELL. Societat. Treballem per millorar la salut de les persones. Col·labora. Recerca. Càncer, neurociències, medicina translacional i regenerativa. Àrees de recerca. Innovació. Del laboratori alTHE INSTITUTE
The Bellvitge Biomedical Research Institute (IDIBELL) is a research center in biomedicine promoted by the Bellvitge University Hospital and l’Viladecans Hospital, both from the Catalan Health Institute, the Catalan Institute of Oncology, University of Barcelona and L’Hospitalet de Llobregat city council.In 2017, the Center for Regenerative Medicine of Barcelona (CMR), now part of IDIBELL RESEARCHERS IDENTIFY THREE CLINICAL PROFILES OF A study published in The Lancet Infectious Diseases, in which Bellvitge University Hospital (HUB) and the Bellvitge Biomedical Research Institute (IDIBELL) have participated, has identified three phenotypes (clinical profiles or forms of patient presentation) of COVID-19, each with a RECERCA – IDIBELLTRANSLATE THIS PAGE L'Institut de Recerca Biomèdica de Bellvitge (IDIBELL) és un centre de recerca orientat vers la millora dels problemes de salut de les persones.Per aconseguir-ho és necessari dur a terme recerca bàsica i clínica d’alt nivell. L’IDIBELL té investigadors propis i integra la recerca que es duu a terme a l’Hospital Universitari de Bellvitge, l’Hospital de Viladecans (ambdós de lOFERTES DE FEINA
Sobre la política de l'IDIBELL de contractació oberta, transparent i basada en el mèrit. L'IDIBELL ha actualitzat l'estratègia de recursos humans i els seus procediments de contractació d'investigadors, suport científic i personal de suport a la gestió per assegurar la selecció dels candidats més idonis mitjançant una contractació oberta, transparent i basada en el mèrit (OTM-R).ARETE.IDIBELL.CAT
2019 Bellvitge Biomedical Research Institute. All rights reserved.X
PHARMACOVIGILANCE TECHNICIAN FOR CLINICAL RESEARCH UNIT IN IDIBELL is looking for Pharmacovigilance Technician (FV) for Clinical Research Unit in Clinical Trials (UICEC IDIBELL) Our institute. IDIBELL is a research center that integrates the biomedical research of the Bellvitge University Hospital (HUB), the Catalan Institute of Oncology (ICO), and the University of Barcelona in the Bellvitge Campus (UB), and the Viladecans Hospital (HV). GABRIEL CAPELLÁ, DIRECTOR OF IDIBELL The Board of Bellvitge Biomedical Research Institute (IDIBELL), in its meeting of December 29 th, has approved the appointment of. Dr. Gabriel Capellá as director of IDIBELL. This decision puts an end to the selection process started last July, when Dr. Jaume Reventós became coordinator of strategy and institutional relations of the General Directorate for Research and Innovation in Health. IDIBELL - INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGETRANSLATE THISPAGE
Encara no heu confirmat l'asistencia al curs de programacio en R programat pel dia 29-30 de juny i 6-7 de juliol, la data limit per fer la confirmaci� es el dia 09/06/2017IDIBELL
Hospital Duran i Reynals 3a planta / Gran Via de l’Hospitalet, 199 08908 Hospitalet de Llobregat IDIBELLTRANSLATE THIS PAGECOL·LABORACONTACTEINTRANETPROVEÏDORSOFERTES DE FEINAACTUALITAT IDIBELL. Societat. Treballem per millorar la salut de les persones. Col·labora. Recerca. Càncer, neurociències, medicina translacional i regenerativa. Àrees de recerca. Innovació. Del laboratori alTHE INSTITUTE
The Bellvitge Biomedical Research Institute (IDIBELL) is a research center in biomedicine promoted by the Bellvitge University Hospital and l’Viladecans Hospital, both from the Catalan Health Institute, the Catalan Institute of Oncology, University of Barcelona and L’Hospitalet de Llobregat city council.In 2017, the Center for Regenerative Medicine of Barcelona (CMR), now part of IDIBELL RESEARCHERS IDENTIFY THREE CLINICAL PROFILES OF A study published in The Lancet Infectious Diseases, in which Bellvitge University Hospital (HUB) and the Bellvitge Biomedical Research Institute (IDIBELL) have participated, has identified three phenotypes (clinical profiles or forms of patient presentation) of COVID-19, each with a RECERCA – IDIBELLTRANSLATE THIS PAGE L'Institut de Recerca Biomèdica de Bellvitge (IDIBELL) és un centre de recerca orientat vers la millora dels problemes de salut de les persones.Per aconseguir-ho és necessari dur a terme recerca bàsica i clínica d’alt nivell. L’IDIBELL té investigadors propis i integra la recerca que es duu a terme a l’Hospital Universitari de Bellvitge, l’Hospital de Viladecans (ambdós de lOFERTES DE FEINA
Sobre la política de l'IDIBELL de contractació oberta, transparent i basada en el mèrit. L'IDIBELL ha actualitzat l'estratègia de recursos humans i els seus procediments de contractació d'investigadors, suport científic i personal de suport a la gestió per assegurar la selecció dels candidats més idonis mitjançant una contractació oberta, transparent i basada en el mèrit (OTM-R).ARETE.IDIBELL.CAT
2019 Bellvitge Biomedical Research Institute. All rights reserved.X
PHARMACOVIGILANCE TECHNICIAN FOR CLINICAL RESEARCH UNIT IN IDIBELL is looking for Pharmacovigilance Technician (FV) for Clinical Research Unit in Clinical Trials (UICEC IDIBELL) Our institute. IDIBELL is a research center that integrates the biomedical research of the Bellvitge University Hospital (HUB), the Catalan Institute of Oncology (ICO), and the University of Barcelona in the Bellvitge Campus (UB), and the Viladecans Hospital (HV). GABRIEL CAPELLÁ, DIRECTOR OF IDIBELL The Board of Bellvitge Biomedical Research Institute (IDIBELL), in its meeting of December 29 th, has approved the appointment of. Dr. Gabriel Capellá as director of IDIBELL. This decision puts an end to the selection process started last July, when Dr. Jaume Reventós became coordinator of strategy and institutional relations of the General Directorate for Research and Innovation in Health. IDIBELL - INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGETRANSLATE THISPAGE
Encara no heu confirmat l'asistencia al curs de programacio en R programat pel dia 29-30 de juny i 6-7 de juliol, la data limit per fer la confirmaci� es el dia 09/06/2017THE INSTITUTE
The Bellvitge Biomedical Research Institute (IDIBELL) is a research center in biomedicine promoted by the Bellvitge University Hospital and l’Viladecans Hospital, both from the Catalan Health Institute, the Catalan Institute of Oncology, University of Barcelona and L’Hospitalet de Llobregat city council.In 2017, the Center for Regenerative Medicine of Barcelona (CMR), now part ofSCIENTIFIC CULTURE
Scientific Culture and Innovation Unit (UCC+i) IDIBELL follows the model on responsible research and innovation (RRI) that the European Union proposes and is developing. Proof of this was the creation, at the end of 2017, of the Scientific Culture and Innovation Unit (UCC+i), accredited by the Spanish Foundation for Science andTechnology (FECyT).
SCIENCE AND PERFORMING ARTS AGAINST STEREOTYPES A study by IDIBELL and UB shows that participation in a workshop combining scientific training and theatre performance reduces implicit biases against physical illnesses THE IMPACT OF THE PANDEMIC ON PEOPLE WITH EATING DISORDERS The impact of the pandemic on people with eating disorders and obesity. Dr. Fernando Fernández-Aranda is a principal investigator in the Psychiatry and Mental Health Group at IDIBELL, coordinator of the Eating Disorders Unit at Bellvitge University Hospital, and Head of the CIBER Obesity and Nutrition Group. He is currently theeditor-in-chief
RECERCA – IDIBELLTRANSLATE THIS PAGE L'Institut de Recerca Biomèdica de Bellvitge (IDIBELL) és un centre de recerca orientat vers la millora dels problemes de salut de les persones.Per aconseguir-ho és necessari dur a terme recerca bàsica i clínica d’alt nivell. L’IDIBELL té investigadors propis i integra la recerca que es duu a terme a l’Hospital Universitari de Bellvitge, l’Hospital de Viladecans (ambdós de l OCCUPATIONAL RISK PREVENTION MANAGER IDIBELL is looking for an Occupational Risk Prevention Manager . Our institute. IDIBELL is a research center that integrates the biomedical research of the Bellvitge University Hospital (HUB), the Catalan Institute of Oncology (ICO), and the University of Barcelona in the Bellvitge Campus (UB), and the Viladecans Hospital (HV). CLINICAL RESEARCH ASSOCIATE FOR THE CLINICAL RESEARCH AND IDIBELL is looking for Clinical Research Associate (CRA) for the Clinical Research and Clinical Trials Unit (UICEC IDIBELL) Our institute. IDIBELL is a research center that integrates the biomedical research of the Bellvitge University Hospital (HUB), the Catalan Institute of Oncology (ICO), and the University of Barcelona in the Bellvitge Campus (UB), and the Viladecans Hospital (HV).AMP IDIBELL
AMP I (1st edition) The Bellvitge Biomedical Research Institute (IDIBELL) held yesterday April 16th the first edition of its. Accelerator Meeting Point, a meeting where CataloniaBio -association of biomedicine and health. companies in Catalonia-, Biocat -institution responsible for the promotion of IDIBELL - BELLVITGE BIOMEDICAL RESEARCH INSTITUTE Domain: www.idibell.cat Owner: Fundació Institut d’Investigació Biomèdica de Bellvitge (IDIBELL). Address: Hospital Duran i Reynals, 3rd floor, Gran Via de l’Hospitalet, 199-203, 08908 L’Hospitalet de Llobregat (Barcelona). Telephone: 93 260 74 11. Electronic mail address: idibell@idibell.cat. Registration data: registered in the Register of Foundations under number 459STEM CELL AGING
Somatic stem cells have the ability to regenerate tissues over time. This capacity declines with age, disrupting tissue maintenance. Understanding how stem cells age and identifying intervention strategies to maintain stem cell regenerative capacity will lead to new therapeutic approaches for maintaining our health as we age.IDIBELL
Hospital Duran i Reynals 3a planta / Gran Via de l’Hospitalet, 199 08908 Hospitalet de LlobregatTHE INSTITUTE
The Bellvitge Biomedical Research Institute (IDIBELL) is a research center in biomedicine promoted by the Bellvitge University Hospital and l’Viladecans Hospital, both from the Catalan Health Institute, the Catalan Institute of Oncology, University of Barcelona and L’Hospitalet de Llobregat city council.In 2017, the Center for Regenerative Medicine of Barcelona (CMR), now part of IDIBELLTRANSLATE THIS PAGE IDIBELL. Societat. Treballem per millorar la salut de les persones. Col·labora. Recerca. Càncer, neurociències, medicina translacional i regenerativa. Àrees de recerca. Innovació. Del laboratori al IDIBELL RESEARCHERS IDENTIFY THREE CLINICAL PROFILES OF A study published in The Lancet Infectious Diseases, in which Bellvitge University Hospital (HUB) and the Bellvitge Biomedical Research Institute (IDIBELL) have participated, has identified three phenotypes (clinical profiles or forms of patient presentation) of COVID-19, each with aSCIENTIFIC CULTURE
Scientific Culture and Innovation Unit (UCC+i) IDIBELL follows the model on responsible research and innovation (RRI) that the European Union proposes and is developing. Proof of this was the creation, at the end of 2017, of the Scientific Culture and Innovation Unit (UCC+i), accredited by the Spanish Foundation for Science andTechnology (FECyT).
SOME DRUGS USED TO REDUCE STOMACH ACID MAY Mortality from colorectal cancer (CRC) could be reduced by the early detection of lesions and through the implementation of population-based screening programs, to detect the largest number of tumors existing in the population before the appearance of symptoms. In this sense, the immunological fecal occult blood test (iFOBT) is a non-invasive test that detects the presence of non-visible bloodARETE.IDIBELL.CAT
2019 Bellvitge Biomedical Research Institute. All rights reserved.X
GABRIEL CAPELLÁ, DIRECTOR OF IDIBELL The Board of Bellvitge Biomedical Research Institute (IDIBELL), in its meeting of December 29 th, has approved the appointment of. Dr. Gabriel Capellá as director of IDIBELL. This decision puts an end to the selection process started last July, when Dr. Jaume Reventós became coordinator of strategy and institutional relations of the General Directorate for Research and Innovation in Health. IDIBELL - BELLVITGE BIOMEDICAL RESEARCH INSTITUTE Domain: www.idibell.cat Owner: Fundació Institut d’Investigació Biomèdica de Bellvitge (IDIBELL). Address: Hospital Duran i Reynals, 3rd floor, Gran Via de l’Hospitalet, 199-203, 08908 L’Hospitalet de Llobregat (Barcelona). Telephone: 93 260 74 11. Electronic mail address: idibell@idibell.cat. Registration data: registered in the Register of Foundations under number 459 IÑAKI MARTIN-SUBERO JOSE IGNACIO MARTIN-SUBERO, PhD. Leader of the Biomedical Epigenomics Group. IDIBAPS/ICREA. Barcelona, Spain. Dr. Martin-Subero graduated from the University of Navarra (Spain) with a degree in Biochemistry. In 2001, he completed a PhD with honours as a joined effort between the University of Navarra and the Christian-Albrechts University ofIDIBELL
Hospital Duran i Reynals 3a planta / Gran Via de l’Hospitalet, 199 08908 Hospitalet de LlobregatTHE INSTITUTE
The Bellvitge Biomedical Research Institute (IDIBELL) is a research center in biomedicine promoted by the Bellvitge University Hospital and l’Viladecans Hospital, both from the Catalan Health Institute, the Catalan Institute of Oncology, University of Barcelona and L’Hospitalet de Llobregat city council.In 2017, the Center for Regenerative Medicine of Barcelona (CMR), now part of IDIBELLTRANSLATE THIS PAGE IDIBELL. Societat. Treballem per millorar la salut de les persones. Col·labora. Recerca. Càncer, neurociències, medicina translacional i regenerativa. Àrees de recerca. Innovació. Del laboratori al IDIBELL RESEARCHERS IDENTIFY THREE CLINICAL PROFILES OF A study published in The Lancet Infectious Diseases, in which Bellvitge University Hospital (HUB) and the Bellvitge Biomedical Research Institute (IDIBELL) have participated, has identified three phenotypes (clinical profiles or forms of patient presentation) of COVID-19, each with aSCIENTIFIC CULTURE
Scientific Culture and Innovation Unit (UCC+i) IDIBELL follows the model on responsible research and innovation (RRI) that the European Union proposes and is developing. Proof of this was the creation, at the end of 2017, of the Scientific Culture and Innovation Unit (UCC+i), accredited by the Spanish Foundation for Science andTechnology (FECyT).
SOME DRUGS USED TO REDUCE STOMACH ACID MAY Mortality from colorectal cancer (CRC) could be reduced by the early detection of lesions and through the implementation of population-based screening programs, to detect the largest number of tumors existing in the population before the appearance of symptoms. In this sense, the immunological fecal occult blood test (iFOBT) is a non-invasive test that detects the presence of non-visible bloodARETE.IDIBELL.CAT
2019 Bellvitge Biomedical Research Institute. All rights reserved.X
GABRIEL CAPELLÁ, DIRECTOR OF IDIBELL The Board of Bellvitge Biomedical Research Institute (IDIBELL), in its meeting of December 29 th, has approved the appointment of. Dr. Gabriel Capellá as director of IDIBELL. This decision puts an end to the selection process started last July, when Dr. Jaume Reventós became coordinator of strategy and institutional relations of the General Directorate for Research and Innovation in Health. IDIBELL - BELLVITGE BIOMEDICAL RESEARCH INSTITUTE Domain: www.idibell.cat Owner: Fundació Institut d’Investigació Biomèdica de Bellvitge (IDIBELL). Address: Hospital Duran i Reynals, 3rd floor, Gran Via de l’Hospitalet, 199-203, 08908 L’Hospitalet de Llobregat (Barcelona). Telephone: 93 260 74 11. Electronic mail address: idibell@idibell.cat. Registration data: registered in the Register of Foundations under number 459 IÑAKI MARTIN-SUBERO JOSE IGNACIO MARTIN-SUBERO, PhD. Leader of the Biomedical Epigenomics Group. IDIBAPS/ICREA. Barcelona, Spain. Dr. Martin-Subero graduated from the University of Navarra (Spain) with a degree in Biochemistry. In 2001, he completed a PhD with honours as a joined effort between the University of Navarra and the Christian-Albrechts University of IDIBELLTRANSLATE THIS PAGE IDIBELL. Societat. Treballem per millorar la salut de les persones. Col·labora. Recerca. Càncer, neurociències, medicina translacional i regenerativa. Àrees de recerca. Innovació. Del laboratori alTHE INSTITUTE
The Bellvitge Biomedical Research Institute (IDIBELL) is a research center in biomedicine promoted by the Bellvitge University Hospital and l’Viladecans Hospital, both from the Catalan Health Institute, the Catalan Institute of Oncology, University of Barcelona and L’Hospitalet de Llobregat city council.In 2017, the Center for Regenerative Medicine of Barcelona (CMR), now part ofSCIENTIFIC CULTURE
Scientific Culture and Innovation Unit (UCC+i) IDIBELL follows the model on responsible research and innovation (RRI) that the European Union proposes and is developing. Proof of this was the creation, at the end of 2017, of the Scientific Culture and Innovation Unit (UCC+i), accredited by the Spanish Foundation for Science andTechnology (FECyT).
SCIENCE AND PERFORMING ARTS AGAINST STEREOTYPES A study by IDIBELL and UB shows that participation in a workshop combining scientific training and theatre performance reduces implicit biases against physical illnesses APTADEL, THE NEW IDIBELL’S SPINOFF Aptadel, the new IDIBELL’s spinoff. Aptadel Therapeutics is a preclinical company co-founded by IDIBELL focused on developing a new platform for targeted therapy against cancer. This platform consists of nanoparticles loaded with therapeutic agents, such as RNA molecules or chemotherapeutic drugs, targeted to different tumors. IDENTIFIED THE CELLULAR PROCESS BY WHICH CISPLATIN Despite the great advances in cancer research in recent years, treatments that can cause very severe adverse effects are still used. This is the case of neuropathy caused by chemotherapy with platinum derivatives, such as Cisplatin and Oxaliplatin.These are widely used drugs that can damage the peripheral nervous system causing a progressive and increasing loss of sensitivity, which may even EXERCISE PREVENTS NEURONAL DAMAGE CAUSED BY LUNG CANCER Lucía Vaquero, first author of the article. In lung cancer patients who have received chemotherapy and/or cranial radiotherapy, physical activity is able to reduce the neuronal damage caused by thetreatment.
OCCUPATIONAL RISK PREVENTION MANAGER IDIBELL is looking for an Occupational Risk Prevention Manager . Our institute. IDIBELL is a research center that integrates the biomedical research of the Bellvitge University Hospital (HUB), the Catalan Institute of Oncology (ICO), and the University of Barcelona in the Bellvitge Campus (UB), and the Viladecans Hospital (HV). CLINICAL TRIAL MANAGER FOR THE CLINICAL RESEARCH UNIT IDIBELL is looking for a Clinical Trial Manager for the Clinical Research Unit . Our institute. IDIBELL is a research center that integrates the biomedical research of the Bellvitge University Hospital (HUB), the Catalan Institute of Oncology (ICO), and the University of Barcelona in the Bellvitge Campus (UB), and the Viladecans Hospital (HV). LABORATORY MANAGER FOR THE CANCER METABOLISM GROUP Categoria: Recerca Data límit: 06/06/202106/06/2021IDIBELL
Hospital Duran i Reynals 3a planta / Gran Via de l’Hospitalet, 199 08908 Hospitalet de LlobregatTHE INSTITUTE
The Bellvitge Biomedical Research Institute (IDIBELL) is a research center in biomedicine promoted by the Bellvitge University Hospital and l’Viladecans Hospital, both from the Catalan Health Institute, the Catalan Institute of Oncology, University of Barcelona and L’Hospitalet de Llobregat city council.In 2017, the Center for Regenerative Medicine of Barcelona (CMR), now part of IDIBELLTRANSLATE THIS PAGE IDIBELL. Societat. Treballem per millorar la salut de les persones. Col·labora. Recerca. Càncer, neurociències, medicina translacional i regenerativa. Àrees de recerca. Innovació. Del laboratori al IDIBELL RESEARCHERS IDENTIFY THREE CLINICAL PROFILES OF A study published in The Lancet Infectious Diseases, in which Bellvitge University Hospital (HUB) and the Bellvitge Biomedical Research Institute (IDIBELL) have participated, has identified three phenotypes (clinical profiles or forms of patient presentation) of COVID-19, each with aSCIENTIFIC CULTURE
Scientific Culture and Innovation Unit (UCC+i) IDIBELL follows the model on responsible research and innovation (RRI) that the European Union proposes and is developing. Proof of this was the creation, at the end of 2017, of the Scientific Culture and Innovation Unit (UCC+i), accredited by the Spanish Foundation for Science andTechnology (FECyT).
SOME DRUGS USED TO REDUCE STOMACH ACID MAY Mortality from colorectal cancer (CRC) could be reduced by the early detection of lesions and through the implementation of population-based screening programs, to detect the largest number of tumors existing in the population before the appearance of symptoms. In this sense, the immunological fecal occult blood test (iFOBT) is a non-invasive test that detects the presence of non-visible bloodARETE.IDIBELL.CAT
2019 Bellvitge Biomedical Research Institute. All rights reserved.X
GABRIEL CAPELLÁ, DIRECTOR OF IDIBELL The Board of Bellvitge Biomedical Research Institute (IDIBELL), in its meeting of December 29 th, has approved the appointment of. Dr. Gabriel Capellá as director of IDIBELL. This decision puts an end to the selection process started last July, when Dr. Jaume Reventós became coordinator of strategy and institutional relations of the General Directorate for Research and Innovation in Health. IDIBELL - BELLVITGE BIOMEDICAL RESEARCH INSTITUTE Domain: www.idibell.cat Owner: Fundació Institut d’Investigació Biomèdica de Bellvitge (IDIBELL). Address: Hospital Duran i Reynals, 3rd floor, Gran Via de l’Hospitalet, 199-203, 08908 L’Hospitalet de Llobregat (Barcelona). Telephone: 93 260 74 11. Electronic mail address: idibell@idibell.cat. Registration data: registered in the Register of Foundations under number 459 IÑAKI MARTIN-SUBERO JOSE IGNACIO MARTIN-SUBERO, PhD. Leader of the Biomedical Epigenomics Group. IDIBAPS/ICREA. Barcelona, Spain. Dr. Martin-Subero graduated from the University of Navarra (Spain) with a degree in Biochemistry. In 2001, he completed a PhD with honours as a joined effort between the University of Navarra and the Christian-Albrechts University ofIDIBELL
Hospital Duran i Reynals 3a planta / Gran Via de l’Hospitalet, 199 08908 Hospitalet de LlobregatTHE INSTITUTE
The Bellvitge Biomedical Research Institute (IDIBELL) is a research center in biomedicine promoted by the Bellvitge University Hospital and l’Viladecans Hospital, both from the Catalan Health Institute, the Catalan Institute of Oncology, University of Barcelona and L’Hospitalet de Llobregat city council.In 2017, the Center for Regenerative Medicine of Barcelona (CMR), now part of IDIBELLTRANSLATE THIS PAGE IDIBELL. Societat. Treballem per millorar la salut de les persones. Col·labora. Recerca. Càncer, neurociències, medicina translacional i regenerativa. Àrees de recerca. Innovació. Del laboratori al IDIBELL RESEARCHERS IDENTIFY THREE CLINICAL PROFILES OF A study published in The Lancet Infectious Diseases, in which Bellvitge University Hospital (HUB) and the Bellvitge Biomedical Research Institute (IDIBELL) have participated, has identified three phenotypes (clinical profiles or forms of patient presentation) of COVID-19, each with aSCIENTIFIC CULTURE
Scientific Culture and Innovation Unit (UCC+i) IDIBELL follows the model on responsible research and innovation (RRI) that the European Union proposes and is developing. Proof of this was the creation, at the end of 2017, of the Scientific Culture and Innovation Unit (UCC+i), accredited by the Spanish Foundation for Science andTechnology (FECyT).
SOME DRUGS USED TO REDUCE STOMACH ACID MAY Mortality from colorectal cancer (CRC) could be reduced by the early detection of lesions and through the implementation of population-based screening programs, to detect the largest number of tumors existing in the population before the appearance of symptoms. In this sense, the immunological fecal occult blood test (iFOBT) is a non-invasive test that detects the presence of non-visible bloodARETE.IDIBELL.CAT
2019 Bellvitge Biomedical Research Institute. All rights reserved.X
GABRIEL CAPELLÁ, DIRECTOR OF IDIBELL The Board of Bellvitge Biomedical Research Institute (IDIBELL), in its meeting of December 29 th, has approved the appointment of. Dr. Gabriel Capellá as director of IDIBELL. This decision puts an end to the selection process started last July, when Dr. Jaume Reventós became coordinator of strategy and institutional relations of the General Directorate for Research and Innovation in Health. IDIBELL - BELLVITGE BIOMEDICAL RESEARCH INSTITUTE Domain: www.idibell.cat Owner: Fundació Institut d’Investigació Biomèdica de Bellvitge (IDIBELL). Address: Hospital Duran i Reynals, 3rd floor, Gran Via de l’Hospitalet, 199-203, 08908 L’Hospitalet de Llobregat (Barcelona). Telephone: 93 260 74 11. Electronic mail address: idibell@idibell.cat. Registration data: registered in the Register of Foundations under number 459 IÑAKI MARTIN-SUBERO JOSE IGNACIO MARTIN-SUBERO, PhD. Leader of the Biomedical Epigenomics Group. IDIBAPS/ICREA. Barcelona, Spain. Dr. Martin-Subero graduated from the University of Navarra (Spain) with a degree in Biochemistry. In 2001, he completed a PhD with honours as a joined effort between the University of Navarra and the Christian-Albrechts University of IDIBELLTRANSLATE THIS PAGE IDIBELL. Societat. Treballem per millorar la salut de les persones. Col·labora. Recerca. Càncer, neurociències, medicina translacional i regenerativa. Àrees de recerca. Innovació. Del laboratori alTHE INSTITUTE
The Bellvitge Biomedical Research Institute (IDIBELL) is a research center in biomedicine promoted by the Bellvitge University Hospital and l’Viladecans Hospital, both from the Catalan Health Institute, the Catalan Institute of Oncology, University of Barcelona and L’Hospitalet de Llobregat city council.In 2017, the Center for Regenerative Medicine of Barcelona (CMR), now part ofSCIENTIFIC CULTURE
Scientific Culture and Innovation Unit (UCC+i) IDIBELL follows the model on responsible research and innovation (RRI) that the European Union proposes and is developing. Proof of this was the creation, at the end of 2017, of the Scientific Culture and Innovation Unit (UCC+i), accredited by the Spanish Foundation for Science andTechnology (FECyT).
SCIENCE AND PERFORMING ARTS AGAINST STEREOTYPES A study by IDIBELL and UB shows that participation in a workshop combining scientific training and theatre performance reduces implicit biases against physical illnesses APTADEL, THE NEW IDIBELL’S SPINOFF Aptadel, the new IDIBELL’s spinoff. Aptadel Therapeutics is a preclinical company co-founded by IDIBELL focused on developing a new platform for targeted therapy against cancer. This platform consists of nanoparticles loaded with therapeutic agents, such as RNA molecules or chemotherapeutic drugs, targeted to different tumors. IDENTIFIED THE CELLULAR PROCESS BY WHICH CISPLATIN Despite the great advances in cancer research in recent years, treatments that can cause very severe adverse effects are still used. This is the case of neuropathy caused by chemotherapy with platinum derivatives, such as Cisplatin and Oxaliplatin.These are widely used drugs that can damage the peripheral nervous system causing a progressive and increasing loss of sensitivity, which may even EXERCISE PREVENTS NEURONAL DAMAGE CAUSED BY LUNG CANCER Lucía Vaquero, first author of the article. In lung cancer patients who have received chemotherapy and/or cranial radiotherapy, physical activity is able to reduce the neuronal damage caused by thetreatment.
OCCUPATIONAL RISK PREVENTION MANAGER IDIBELL is looking for an Occupational Risk Prevention Manager . Our institute. IDIBELL is a research center that integrates the biomedical research of the Bellvitge University Hospital (HUB), the Catalan Institute of Oncology (ICO), and the University of Barcelona in the Bellvitge Campus (UB), and the Viladecans Hospital (HV). CLINICAL TRIAL MANAGER FOR THE CLINICAL RESEARCH UNIT IDIBELL is looking for a Clinical Trial Manager for the Clinical Research Unit . Our institute. IDIBELL is a research center that integrates the biomedical research of the Bellvitge University Hospital (HUB), the Catalan Institute of Oncology (ICO), and the University of Barcelona in the Bellvitge Campus (UB), and the Viladecans Hospital (HV). LABORATORY MANAGER FOR THE CANCER METABOLISM GROUP Categoria: Recerca Data límit: 06/06/202106/06/2021IDIBELL
Hospital Duran i Reynals 3a planta / Gran Via de l’Hospitalet, 199 08908 Hospitalet de LlobregatTHE INSTITUTE
The Bellvitge Biomedical Research Institute (IDIBELL) is a research center in biomedicine promoted by the Bellvitge University Hospital and l’Viladecans Hospital, both from the Catalan Health Institute, the Catalan Institute of Oncology, University of Barcelona and L’Hospitalet de Llobregat city council.In 2017, the Center for Regenerative Medicine of Barcelona (CMR), now part of IDIBELL RESEARCHERS IDENTIFY THREE CLINICAL PROFILES OF A study published in The Lancet Infectious Diseases, in which Bellvitge University Hospital (HUB) and the Bellvitge Biomedical Research Institute (IDIBELL) have participated, has identified three phenotypes (clinical profiles or forms of patient presentation) of COVID-19, each with a IDIBELLTRANSLATE THIS PAGE IDIBELL. Societat. Treballem per millorar la salut de les persones. Col·labora. Recerca. Càncer, neurociències, medicina translacional i regenerativa. Àrees de recerca. Innovació. Del laboratori alSCIENTIFIC CULTURE
Scientific Culture and Innovation Unit (UCC+i) IDIBELL follows the model on responsible research and innovation (RRI) that the European Union proposes and is developing. Proof of this was the creation, at the end of 2017, of the Scientific Culture and Innovation Unit (UCC+i), accredited by the Spanish Foundation for Science andTechnology (FECyT).
NEW MUSCULAR DISEASE: MYOGLOBINOPATHY Myoglobinopathy, the name that has been proposed for the new disease, manifests between the fourth and fifth decade of life. It causes a progressive weakness of the axial and limb muscles, and in more advanced stages affects the respiratory musculature and the heart. The study has also involved, among others, researchers from the ALBAARETE.IDIBELL.CAT
2019 Bellvitge Biomedical Research Institute. All rights reserved.X
GABRIEL CAPELLÁ, DIRECTOR OF IDIBELL The Board of Bellvitge Biomedical Research Institute (IDIBELL), in its meeting of December 29 th, has approved the appointment of. Dr. Gabriel Capellá as director of IDIBELL. This decision puts an end to the selection process started last July, when Dr. Jaume Reventós became coordinator of strategy and institutional relations of the General Directorate for Research and Innovation in Health. PSIQUIATRÍA Y SALUD MENTAL A prospective international multi-center study on safety and efficacy of deep brain stimulation for resistant obsessive-compulsive disorder. Menchón JM, Real E, Alonso P, Aparicio MA, Segalas C, Plans G, Luyten L, Brunfaut E, Matthijs L, Raymakers S, Bervoets C, Higueras A, Katati M, Guerrero J, Hurtado M, Prieto M, Stieglitz LH, Löffelholz G, Walther S, Pollo C, Zurowski B, Tronnier V IÑAKI MARTIN-SUBERO JOSE IGNACIO MARTIN-SUBERO, PhD. Leader of the Biomedical Epigenomics Group. IDIBAPS/ICREA. Barcelona, Spain. Dr. Martin-Subero graduated from the University of Navarra (Spain) with a degree in Biochemistry. In 2001, he completed a PhD with honours as a joined effort between the University of Navarra and the Christian-Albrechts University ofIDIBELL
Hospital Duran i Reynals 3a planta / Gran Via de l’Hospitalet, 199 08908 Hospitalet de LlobregatTHE INSTITUTE
The Bellvitge Biomedical Research Institute (IDIBELL) is a research center in biomedicine promoted by the Bellvitge University Hospital and l’Viladecans Hospital, both from the Catalan Health Institute, the Catalan Institute of Oncology, University of Barcelona and L’Hospitalet de Llobregat city council.In 2017, the Center for Regenerative Medicine of Barcelona (CMR), now part of IDIBELL RESEARCHERS IDENTIFY THREE CLINICAL PROFILES OF A study published in The Lancet Infectious Diseases, in which Bellvitge University Hospital (HUB) and the Bellvitge Biomedical Research Institute (IDIBELL) have participated, has identified three phenotypes (clinical profiles or forms of patient presentation) of COVID-19, each with a IDIBELLTRANSLATE THIS PAGE IDIBELL. Societat. Treballem per millorar la salut de les persones. Col·labora. Recerca. Càncer, neurociències, medicina translacional i regenerativa. Àrees de recerca. Innovació. Del laboratori alSCIENTIFIC CULTURE
Scientific Culture and Innovation Unit (UCC+i) IDIBELL follows the model on responsible research and innovation (RRI) that the European Union proposes and is developing. Proof of this was the creation, at the end of 2017, of the Scientific Culture and Innovation Unit (UCC+i), accredited by the Spanish Foundation for Science andTechnology (FECyT).
NEW MUSCULAR DISEASE: MYOGLOBINOPATHY Myoglobinopathy, the name that has been proposed for the new disease, manifests between the fourth and fifth decade of life. It causes a progressive weakness of the axial and limb muscles, and in more advanced stages affects the respiratory musculature and the heart. The study has also involved, among others, researchers from the ALBAARETE.IDIBELL.CAT
2019 Bellvitge Biomedical Research Institute. All rights reserved.X
GABRIEL CAPELLÁ, DIRECTOR OF IDIBELL The Board of Bellvitge Biomedical Research Institute (IDIBELL), in its meeting of December 29 th, has approved the appointment of. Dr. Gabriel Capellá as director of IDIBELL. This decision puts an end to the selection process started last July, when Dr. Jaume Reventós became coordinator of strategy and institutional relations of the General Directorate for Research and Innovation in Health. PSIQUIATRÍA Y SALUD MENTAL A prospective international multi-center study on safety and efficacy of deep brain stimulation for resistant obsessive-compulsive disorder. Menchón JM, Real E, Alonso P, Aparicio MA, Segalas C, Plans G, Luyten L, Brunfaut E, Matthijs L, Raymakers S, Bervoets C, Higueras A, Katati M, Guerrero J, Hurtado M, Prieto M, Stieglitz LH, Löffelholz G, Walther S, Pollo C, Zurowski B, Tronnier V IÑAKI MARTIN-SUBERO JOSE IGNACIO MARTIN-SUBERO, PhD. Leader of the Biomedical Epigenomics Group. IDIBAPS/ICREA. Barcelona, Spain. Dr. Martin-Subero graduated from the University of Navarra (Spain) with a degree in Biochemistry. In 2001, he completed a PhD with honours as a joined effort between the University of Navarra and the Christian-Albrechts University of IDIBELLTRANSLATE THIS PAGE IDIBELL. Societat. Treballem per millorar la salut de les persones. Col·labora. Recerca. Càncer, neurociències, medicina translacional i regenerativa. Àrees de recerca. Innovació. Del laboratori alTHE INSTITUTE
The Bellvitge Biomedical Research Institute (IDIBELL) is a research center in biomedicine promoted by the Bellvitge University Hospital and l’Viladecans Hospital, both from the Catalan Health Institute, the Catalan Institute of Oncology, University of Barcelona and L’Hospitalet de Llobregat city council.In 2017, the Center for Regenerative Medicine of Barcelona (CMR), now part of THE IMPACT OF THE PANDEMIC ON PEOPLE WITH EATING DISORDERS The impact of the pandemic on people with eating disorders and obesity. Dr. Fernando Fernández-Aranda is a principal investigator in the Psychiatry and Mental Health Group at IDIBELL, coordinator of the Eating Disorders Unit at Bellvitge University Hospital, and Head of the CIBER Obesity and Nutrition Group. He is currently theeditor-in-chief
SCIENCE AND PERFORMING ARTS AGAINST STEREOTYPES A study by IDIBELL and UB shows that participation in a workshop combining scientific training and theatre performance reduces implicit biases against physical illnesses JUNE 2021 – IDIBELL An international study, with the participation of IDIBELL and ICO, determines that the metabolism of breast tumor cells is defined bytheir origin.
IDENTIFIED THE CELLULAR PROCESS BY WHICH CISPLATIN Despite the great advances in cancer research in recent years, treatments that can cause very severe adverse effects are still used. This is the case of neuropathy caused by chemotherapy with platinum derivatives, such as Cisplatin and Oxaliplatin.These are widely used drugs that can damage the peripheral nervous system causing a progressive and increasing loss of sensitivity, which may even EXERCISE PREVENTS NEURONAL DAMAGE CAUSED BY LUNG CANCER Lucía Vaquero, first author of the article. In lung cancer patients who have received chemotherapy and/or cranial radiotherapy, physical activity is able to reduce the neuronal damage caused by thetreatment.
OCCUPATIONAL RISK PREVENTION MANAGER IDIBELL is looking for an Occupational Risk Prevention Manager . Our institute. IDIBELL is a research center that integrates the biomedical research of the Bellvitge University Hospital (HUB), the Catalan Institute of Oncology (ICO), and the University of Barcelona in the Bellvitge Campus (UB), and the Viladecans Hospital (HV). CLINICAL TRIAL MANAGER FOR THE CLINICAL RESEARCH UNIT IDIBELL is looking for a Clinical Trial Manager for the Clinical Research Unit . Our institute. IDIBELL is a research center that integrates the biomedical research of the Bellvitge University Hospital (HUB), the Catalan Institute of Oncology (ICO), and the University of Barcelona in the Bellvitge Campus (UB), and the Viladecans Hospital (HV). LABORATORY MANAGER FOR THE CANCER METABOLISM GROUP Categoria: Recerca Data límit: 06/06/202106/06/2021Vés al contingut
Menú principalMenú principal* Col·labora!
* Contacte
* Directori de personal* Intranet
* Proveïdors
* Ca Alternar menú
* Es
* En
*
Cerca Cerca per: __
Below Header
* L’institut
* Recerca
* Serveis
* Innovació
* Actualitat
* Cultura científica SOCIETAT. TREBALLEM PER MILLORAR LA SALUT DE LES PERSONESCol·labora
RECERCA. CÀNCER, NEUROCIÈNCIES, MEDICINA TRANSLACIONAL IREGENERATIVA
Àrees de recerca
INNOVACIÓ. DEL LABORATORI AL PACIENTCom ho fem?
SOCIETAT. TREBALLEM PER MILLORAR LA SALUT DE LES PERSONESCol·labora
RECERCA. CÀNCER, NEUROCIÈNCIES, MEDICINA TRANSLACIONAL IREGENERATIVA
Àrees de recerca
Memòria d'activitats Projectes d'innovacióOfertes de feina
Col·labora
ÚLTIMES NOTÍCIES
07
juny
CIÈNCIA I ARTS ESCÈNIQUES CONTRA ELS ESTEREOTIPS03
juny
L’EXERCICI EVITA EL DANY NEURONAL CAUSAT PER LA TERÀPIA CONTRA ELCÀNCER DE PULMÓ
01
juny
LA DEFINICIÓ DE LES CARACTERÍSTIQUES METABÒLIQUES DEL CÀNCER DE MAMA OBRE LES PORTES A NOVES ESTRATÈGIES TERAPÈUTIQUES31
maig
ESTUDIEN LA REPROGRAMACIÓ DEL METABOLISME DELS LÍPIDS PER COMBATRE L’HEPATOCARCINOMA CEL·LULAR28
maig
FAN SERVIR UN MODEL DE RATOLÍ PER PREDIR LA RESPOSTA AL TRACTAMENT D’UN PACIENT AMB MIELOMASALVEM VIDES
En els darrers anys hem avançat molt, però necessitem seguir investigant per reduir el temps de diagnòstic i aconseguir curar les malalties en el nombre més gran de persones possible. Ens ajudes? Uneix-te a la campanya! ESDEVENIMENTS DESTACATS #IDIBELLSEMINARS: TUMOR CELL-INTRINSIC AND -EXTRINSIC ROLES OF THE INTEGRATED STRESS RESPONSE IN MALIGNANT PROGRESSION AND METASTASIS11/06/2021
-------------------------ÚLTIMS TWEETS
SEMINARIS IDIBELL
INVESTIGADORS DE TOT EL MÓN COMPARTEIXEN LA SEVA RECERCA PRÀCTIQUES CURRICULARS UNA OPORTUNITAT DE DESCOBRIR L’IDIBELL PER DINSDIVULGACIÓ
CULTURA CIENTÍFICA I DIVULGACIÓ PER A TOTS ELS PÚBLICSPROGRAMA ARETÉ
UN PROGRAMA FORMATIU INTERDISCIPLINARI PER AL PERSONAL IDIBELLPATRONAT I SOCIS
DISTINCIONS
MEMBRE DE
FINANÇADORS
ENLLAÇOS DIRECTES
* Repositori Open Access * Comitès i comissions* Transparència
* Avís legal
* Política de privacitat * Política de privacitat XXSSSEGUEIX-NOS
* Youtube
CONTACTE
+34 93 260 77 75
idibell@idibell.cat
UBICACIÓ
Hospital Duran i Reynals 3a planta / Gran Via de l’Hospitalet, 19908908
Hospitalet de Llobregat Copyright © 2021 Institut d’Investigació Biomèdica de BellvitgeScroll to Top
Aquesta web utilitza cookies pròpies per millorar l’experiència de navegació. Més informacióAccepto
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0